Abstract
Purpose: Varenicline, the newest agent marketed for smoking cessation is regarded as effective in providing prolonged smoking abstinence. However, its adverse effect profile may cause discontinuation, potentially reducing smoking abstinence rates, thus requiring an examination of the frequency and impact of adverse effects on discontinuation.
Methods: We sought only Randomised Controlled Trials (RCTs) evaluating the effectiveness and safety of varenicline on humans, with a follow-up period of at least three months and an average Fagerstrom Test for Nicotine Dependence (FTND) score at least 5 (moderate dependence) for both the active and placebo groups. PubMed, Medscape, JCU One Search, ClinicalTrials.gov (U.S.), and the Cochrane Collaboration from January 2006 to January 2015 were searched. Fixed and random effects models were run to determine relationships between adverse effects and premature discontinuation from varenicline.
Results: 12 RCTs were included, involving 5 459 patients, with those receiving varenicline found to be nearly twice as likely (Odds ratio (OR) = 1.82 [1.47; 2.26]) to experience adverse effects compared to those patients on a placebo. The active group experienced nearly a 1.5 times higher (OR = 1.47 [1.19; 1.81]) rate of discontinuation. Nausea, insomnia, and headache are the most commonly reported adverse effects, with ORs of 4.40 [3.80; 5.11], 1.75 [1.48; 2.08], and 1.20 [1.02; 1.41] respectively.
Conclusion: Adverse effects experienced during varenicline treatment appear to be associated with higher discontinuation, which are linked to lowered smoking cessation rates, suggesting a need for strategies to minimise the impacts of adverse effects, to better ensure adherence.
Keywords: Adherence, adverse effects, nicotine addiction, smoking cessation, varenicline
Graphical Abstract
Current Drug Safety
Title:Adverse Effects Cause Varenicline Discontinuation: A Meta-Analysis
Volume: 11 Issue: 1
Author(s): Aaron D. Drovandi, Carla C. Chen and Beverley D. Glass
Affiliation:
Keywords: Adherence, adverse effects, nicotine addiction, smoking cessation, varenicline
Abstract: Purpose: Varenicline, the newest agent marketed for smoking cessation is regarded as effective in providing prolonged smoking abstinence. However, its adverse effect profile may cause discontinuation, potentially reducing smoking abstinence rates, thus requiring an examination of the frequency and impact of adverse effects on discontinuation.
Methods: We sought only Randomised Controlled Trials (RCTs) evaluating the effectiveness and safety of varenicline on humans, with a follow-up period of at least three months and an average Fagerstrom Test for Nicotine Dependence (FTND) score at least 5 (moderate dependence) for both the active and placebo groups. PubMed, Medscape, JCU One Search, ClinicalTrials.gov (U.S.), and the Cochrane Collaboration from January 2006 to January 2015 were searched. Fixed and random effects models were run to determine relationships between adverse effects and premature discontinuation from varenicline.
Results: 12 RCTs were included, involving 5 459 patients, with those receiving varenicline found to be nearly twice as likely (Odds ratio (OR) = 1.82 [1.47; 2.26]) to experience adverse effects compared to those patients on a placebo. The active group experienced nearly a 1.5 times higher (OR = 1.47 [1.19; 1.81]) rate of discontinuation. Nausea, insomnia, and headache are the most commonly reported adverse effects, with ORs of 4.40 [3.80; 5.11], 1.75 [1.48; 2.08], and 1.20 [1.02; 1.41] respectively.
Conclusion: Adverse effects experienced during varenicline treatment appear to be associated with higher discontinuation, which are linked to lowered smoking cessation rates, suggesting a need for strategies to minimise the impacts of adverse effects, to better ensure adherence.
Export Options
About this article
Cite this article as:
Drovandi D. Aaron, Chen C. Carla and Glass D. Beverley, Adverse Effects Cause Varenicline Discontinuation: A Meta-Analysis, Current Drug Safety 2016; 11 (1) . https://dx.doi.org/10.2174/1574886311207040282
DOI https://dx.doi.org/10.2174/1574886311207040282 |
Print ISSN 1574-8863 |
Publisher Name Bentham Science Publisher |
Online ISSN 2212-3911 |

- Author Guidelines
- Bentham Author Support Services (BASS)
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Patents in the Diagnosis and Therapy of Neurocardiogenic Syncope
Recent Patents on Cardiovascular Drug Discovery Evidence-Based Pharmacological Treatment of Substance Use Disorders and Pathological Gambling
Current Drug Abuse Reviews Different Generations of Type-B Monoamine Oxidase Inhibitors in Parkinson’s Disease: From Bench to Bedside
Current Neuropharmacology Technology-Dependent Children: The Chronically Ventilated Child
Current Pediatric Reviews GDNF Family Ligands: A Potential Future for Parkinson's Disease Therapy
CNS & Neurological Disorders - Drug Targets Chemical Composition Analysis and <i>In Vivo</i> Anti-diabetic Activity of Aqueous Extract of Aerial Part of <i>Pallenis spinosa</i> in Diabetic Rats
Current Bioactive Compounds Schizophrenia: Causes and Treatments
Current Pharmaceutical Design Coenzyme Q10 in Neuromuscular and Neurodegenerative Disorders
Current Drug Targets Migraine and Central Sensitization: Clinical Features, Main Comorbidities and Therapeutic Perspectives
Current Rheumatology Reviews The Serotonergic System: Its Role in Pathogenesis and Early Developmental Treatment of Autism
Current Neuropharmacology Melatonin in Autism Spectrum Disorders
Current Clinical Pharmacology Diabetic Theory in Anti-Alzheimer’s Drug Research and Development. Part 2: Therapeutic Potential of cAMP-Specific Phosphodiesterase Inhibitors
Current Medicinal Chemistry Chinese Herbs as Immunomodulators and Potential Disease-Modifying Antirheumatic Drugs in Autoimmune Disorders
Current Drug Metabolism Role of Vitamin A in T Cell Homing to the Gut
Current Immunology Reviews (Discontinued) Levofloxacin-Induced Delirium in a Patient Suffering from Schizoaffective Disorder and Multiple Sclerosis
Current Drug Safety Oxidative stress and Parkinson’s disease: New hopes in treatment with herbal antioxidants
Current Pharmaceutical Design Emerging Therapies in Relapsing-Remitting Multiple Sclerosis
Reviews on Recent Clinical Trials Hypertension in Pregnancy: Clinical Manifestations and Treatment
Current Hypertension Reviews Human Platelets Express Authentic CB1 and CB2 Receptors
Current Neurovascular Research Evaluation of the Fibromyalgia and Related Risk Factors in Patients with Advanced Kidney Failure Undergoing Hemodialysis
Current Rheumatology Reviews